Europe Cancer Tissue Diagnostics Market Growth and Recent Trends by 2027

Europe Cancer Tissue Diagnostics Market to 2027 - Regional Analysis and Forecasts by Test Type (Immunohistochemical Tests and In Situ Hybridization Tests), and Country

Historic Data: 2016-2017   |   Base Year: 2018   |   Forecast Period: 2019-2027
  • Status : Published
  • Report Code : TIPRE00006840
  • Category : Life Sciences
  • No. of Pages : 137
  • Available Report Formats : pdf-format excel-format
Buy Now
Europe Cancer Tissue Diagnostics Market Growth and Recent Trends by 2027
Report Date: Oct 2019   |   Report Code: TIPRE00006840 Email: sales@theinsightpartners.com
Buy Now

Cancer Tissue Diagnostics market in Europe is expected to grow from US$ 512.73 Mn in the year 2018 and is expected to reach US$ 830.28 Mn by 2027 growing at a CAGR of 5.8% over the forecast period.

The growth of the market is driven by the factors such as increasing number of cancer cases and rising geriatric population. On the other hand, high cost of cancer diagnostics in some of the European countries is limiting the growth of market is likely to have a negative impact on the growth of the market in the coming years.

Cancer is among the leading cause of deaths across Europe globe and is profoundly affecting the quality of life. Thus, cancer will be a burden on society if not diagnosed and treated on time. According to the World Health Organization in 2018, approximately 9.6 million deaths across the globe were due to cancer. Additionally, cancer is found to be commonly prevalent in European countries as well. As per the Cancer Research UK, in 2016, around 163,444 deaths in the UK were due to cancer.

The World Health Organization (WHO) also reported that with over 3.7 million new cases and 1.9 million deaths each year, cancer is the second most important cause of morbidity and death in Europe. Moreover, Europe comprises of one-eighth of the total world population, however approximately a quarter of global cancer cases with 3.7 million new patients are from Europe, suggesting high incidence rate of cancer in the region. Furthermore, the data also suggests that 40% of these cancer cases are preventable with appropriate diagnosis at early stages and correct treatment and medication.

The Spain Cancer Tissue Diagnostics market is expected to grow at highest rate during the forecast period owing to various cancer research studies undergoing in the country, increasing number of cancer patients in the country, and various solutions undertaken to reduce the financial burden due to cancer on the country. Moreover, the country also is the fastest growing among other European countries owing to the increasing medical tourism flourishing in Spain.

Spain Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)

TIPRE00006840-img1

  • This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
 

EUROPE CANCER TISSUE DIAGNOSTICS – MARKET SEGMENTATION

By Test Type

  • Immunohistochemical Tests
    • Breast Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Others
  • In Situ Hybridization Tests
    • Breast Cancer
    • Lung Cancer
    • Bladder Cancer
    • Others

By Country

  • France
  • Germany
  • UK
  • Italy
  • Spain

Companies Mentioned

  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Bio Rad Laboratories Inc.
  • Abbott
  • Enzo Life Sciences, Inc.
  • Agilent Technologies, Inc.
  • Cancer Genetics Inc.
  • Merck KGaA (Sigma-Aldrich Co. LLC)
  • Danaher
  • Abcam plc.

Europe Cancer Tissue Diagnostics Report Scope

Report Attribute Details
Market size in 2018 US$ 512.73 Million
Market Size by 2027 US$ 830.28 Million
CAGR (2019 - 2027) 5.8%
Historical Data 2016-2017
Forecast period 2019-2027
Segments Covered By Test Type
  • Immunohistochemical Tests and In Situ Hybridization Tests
Regions and Countries Covered Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Market leaders and key company profiles
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Bio Rad Laboratories Inc.
  • Abbott
  • Enzo Life Sciences, Inc.
  • Agilent Technologies, Inc.
  • Cancer Genetics Inc.
  • Merck KGaA (Sigma-Aldrich Co. LLC)
  • Danaher
  • Abcam plc.
Mrinal Kerhalkar
Manager,
Market Research & Consulting

Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

  • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
  • PEST and SWOT Analysis
  • Market Size Value / Volume - Regional, Country
  • Industry and Competitive Landscape
  • Excel Dataset

Testimonials

Reason to Buy

  • Informed Decision-Making
  • Understanding Market Dynamics
  • Competitive Analysis
  • Identifying Emerging Markets
  • Customer Insights
  • Market Forecasts
  • Risk Mitigation
  • Boosting Operational Efficiency
  • Strategic Planning
  • Investment Justification
  • Tracking Industry Innovations
  • Aligning with Regulatory Trends
☀️ Eligible for Summer Discount
Unlock Exclusive Report Discounts
Enquire Now
Sales Assistance
US: +1-646-491-9876
UK: +44-20-8125-4005
Chat with us
DUNS Logo
ISO Certified Logo
GDPR
CCPA
Page Updated: Feb 2025